Neuroimaging findings in children with paediatric neurotransmitter diseases

Journal of Inherited Metabolic Disease

Volumn 32, Issue 3, 2009, Pages 361-370

  Lee, Wang Tso ^a   Weng, Wen Chin ^a   Peng, Shinn Forng ^a   Tzen, Kai Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBON 11; DIHYDROTETRABENAZINE; FLUORODEOXYGLUCOSE F 18; IODINE 123; METHYLPHENIDATE; MONOAMINE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROTRANSMITTER; SEPIAPTERIN REDUCTASE; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; TYROSINE 3 MONOOXYGENASE;

4 AMINOBUTYRIC ACID METABOLISM; AROMATIC LEVO AMINO ACID DECARBOXYLASE DEFICIENCY; AUTOSOMAL DISORDER; CEREBROSPINAL FLUID LEVEL; CHILDHOOD DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; ENZYME DEFICIENCY; HUMAN; METABOLIC DISORDER; MONOAMINE METABOLISM; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; PEDIATRIC NEUROTRANSMITTER DISEASE; PEDIATRICIAN; POSITRON EMISSION TOMOGRAPHY; SEGAWA DISEASE; SEPIAPTERIN REDUCTASE DEFICIENCY; SUCCINATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; TYROSINE HYDROXYLASE DEFICIENCY;

ALCOHOL OXIDOREDUCTASES; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; CHILD; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; MODELS, BIOLOGICAL; NEUROTRANSMITTER AGENTS; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE; TYROSINE 3-MONOOXYGENASE;

EID: 67349098449     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1106-z     Document Type: Conference Paper

References (57)

1. Abeling NG, Duran M, Bakker HD, et al (2006) Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab 89: 116-120. doi: 10.1016/j.ymgme.2006.03.010
2. Akaboshi S, Hogema BM, Novelletto A, et al (2003) Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat 22: 442-450
3. Al-Essa MA, Bakheet SM, Patay ZJ, Powe JE, Ozand PT (2000) Clinical, FDG PET, MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria: A progressive neurometabolic disease. Brain Dev 22: 127-131. doi: 10.1016/S0387-7604(99)00121-7
4. Anselm IA, Darras BT (2006) Catecholamine toxicity in aromatic l-amino acid decarboxylase deficiency. Pediatr Neurol 35: 142-144. doi: 10.1016/ j.pediatrneurol.2006.01.008
5. Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5: 165-176.
6. Booij J, Halraken JBA, Bergmans P, et al (1998) Imaging of dopamine transporter with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 39: 1879-1884.
7. Bräutigam C, Wevers RA, Jansen RJ, et al (1998) Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 44: 1897-1904.
8. Bräutigam C, Hyland K, Wevers R, et al (2002) Clinical and laboratory findings in twins with neonatal epileptic encephalopathy mimicking aromatic l-amino acid decarboxylase deficiency. Neuropediatrics 33: 113-117. doi: 10.1055/s-2002-33673
9. 11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm 113: 187-193. doi: 10.1007/ s00702-005-0311-7
10. Buu NT (1989) Vesicular accumulation of dopamine following L-DOPA administration. Biochem Pharmacol 38: 1787-1792. doi: 10.1016/ 0006-2952(89)90413-9
11. Chan AS, Ng LW, Poon LS, Chan WW, Wong YH (2007) Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. Apoptosis 12: 167-179. doi: 10.1007/s10495-006-0524-8
12. De Lonlay P, Nassogne MC, van Gennip AH, et al (2000) Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation. J Inherit Metab Dis 23: 819-825. doi: 10.1023/A:1026760602577
13. Dionisi-Vici C, Hoffmann GF, Leuzzi V, et al (2000) Tyrosine hydroxylase deficiency with severe clinical course: Clinical and biochemical investigations and optimization of therapy. J Pediatr 136: 560-562. doi: 10.1016/S0022-3476(00)90027-1
14. de Rijk-Van Andel JF, Gabreëls FJ, et al (2000) L-Dopa responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology 55: 1926-1928.
15. Echenne B, Roubertie A, Assmann B, et al (2006) Sepiapterin reductase deficiency: Clinical presentation and evaluation of long-term therapy. Pediatr Neurol 35: 308-313. doi: 10.1016/j.pediatrneurol.2006.05.006
16. 123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 76: 1211-1216. doi: 10.1136/jnnp.2004.045237
17. Ethofer T, Seeger U, Klose U, et al (2004) Proton MR spectroscopy in succinic semialdehyde dehydrogenase deficiency. Neurology 62: 1016-1018.
18. Friedman J, Hyland K, Blau N, MacCollin M (2006) Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology 67: 2032-2035. doi: 10.1212/ 01.wnl.0000247274.21261.b4
19. Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ (2001) Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 56: 260-263.
20. Gaspar P, Cases O, Maroteaux L (2003) The developmental role of serotonin: News from mouse molecular genetics. Nat Rev Neurosci 4: 1002-1012. doi: 10.1038/nrn1256
21. Gibson KM, Christensen E, Jakobs C, et al (1997) The clinical phenotype of SSADH deficiency: Case reports of 23 new patients. Pediatrics 99: 567-574. doi: 10.1542/peds.99.4.567
22. Harper A, Bayliss M, Saha R, Scutt A, Nisbet A (2008) Late onset dopa-responsive dystonia with tremor, gait freezing and behavioural disturbance and a normal dopamine transporter scan. Age Ageing 37: 719-720. doi: 10.1093/ageing/afn216
23. Hoffmann GF, Assmann B, Bräutigam C, et al (2003) Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 54 Supplement 6:S56-65. doi: 10.1002/ana.10632
24. Horn AS (1990) Dopamine uptake: A review of progress in the last decade. Prog Neurobiol 34: 387-400. doi: 10.1016/0301-0082(90)90033-D
25. Huang CC, Yen TC, Weng YH, Lu CS (2002) Normal dopamine transporter binding in dopa responsive dystonia. J Neurol 249: 1016-1020. doi: 10.1007/s00415-002-0776-3
26. 99m Tc]TRODAT-1/[123I]IBZM SPECT imaging findings in dopa-responsive dystonia. Eur Neurol 51: 26-29. doi: 10.1159/000074914
27. Hyland K, Clayton PT (1990) Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis 13: 301-304. doi: 10.1007/BF01799380
28. Hyland K, Surtees RAH, Rodeck C, Clayton PT (1992) Aromatic l-amino acid decarboxylase deficiency: Clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42: 1980-1988.
29. Jenner PG, Brin MF (1998) Levodopa neurotoxicity: Experimental studies versus clinical relevance. Neurology 50 (6 Suppl 6):S39-S43.
30. Knappskog PM, Flatmark T, Mallet J, Lüdecke B, Bartholomé K (1995) Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 4: 1209-1212. doi: 10.1093/hmg/4.7.1209
31. 99mTc]TRODAT. Nucl Med Biol 34: 787-789. doi: 10.1016/j.nucmedbio.2007.03.010
32. Latini A, Scussiato K, Leipnitz G, et al (2007) Evidence for oxidative stress in tissues derived from succinate semialdehyde dehydrogenase-deficient mice. J Inherit Metab Dis 30: 800-810. doi: 10.1007/s10545-007-0599-6
33. Lee CS, Samii A, Sossi V, et al (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47: 493-503.
34. Lu CS, Chang HC, Kuo PC, et al (2004) The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. Parkinsonism Relat Disord 10: 369-373. doi: 10.1016/j.parkreldis.2004.03.009
35. Martin WR, Palmer MR, Patlak CS, Calne DB (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 26: 535-542. doi: 10.1002/ana.410260407
36. Martin WR, Wieler M, Stoessl AJ, Schulzer M (2008) Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 63: 388-394. doi: 10.1002/ana.21320
37. Miller DW, Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: Studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72: 1516-1522. doi: 10.1046/ j.1471-4159.1999.721516.x
38. Nagata E, Kosakai A, Tanaka K, et al (2007) Dopa-responsive dystonia (Segawa disease)-like disease accompanied by mental retardation: A case report. Mov Disord 22: 1202-1203. doi: 10.1002/mds.21517
39. Neville BG, Parascandalo R, Farrugia R, Felice A (2005) Sepiapterin reductase deficiency: A congenital dopa-responsive motor and cognitive disorder. Brain 128 Pt 10:2291-2296. doi: 10.1093/brain/awh603
40. Pearl PL, Gibson KM, Acosta MT, et al (2003a) Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 60: 1413-1417.
41. Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM (2003b) Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 54 (Suppl 6):S73-80. doi: 10.1002/ana.10629
42. Pearl PL, Gibson KM (2004) Clinical aspects of the disorders of GABA metabolism in children. Curr Opin Neurol 17: 107-113. doi: 10.1097/ 00019052-200404000-00005
43. Pearl PL, Vezina LG, Saneto RP, et al (2009) Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 50: 184-194. doi: 10.1111/ j.1528-1167.2008.01728.x
44. Pons R, Ford B, Chiriboga CA, et al (2004) Aromatic l-amino acid decarboxylase deficiency: Clinical features, treatment and prognosis. Neurology 62: 1058-1065.
45. Sawle GV, Leenders KL, Brooks DJ, et al (1991) Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann Neurol 30: 24-30. doi: 10.1002/ana.410300106
46. Schiller A, Wevers RA, Steenbergen GC, Blau N, Jung HH (2004) Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology 63: 1524-1526.
47. Snow BJ, Nygaard TG, Takahashi H, Calne DB (1993) Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 34: 733-738. doi: 10.1002/ ana.410340518
48. Swoboda KJ, Hyland K, Goldstein DS, et al (1999) Clinical and therapeutic observations in aromatic l-amino acid decarboxylase deficiency. Neurology 53: 1205-1211.
49. Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K (2003) Aromatic l-amino acid decarboxylase deficiency: Overview of clinical features and outcomes. Ann Neurol 54 (Suppl 6):S49-S55. doi: 10.1002/ana.10631
50. Tennison M (1999) Focal lesion in the splenium of the corpus callosum in epileptic patients: Antiepileptic drug toxicity? AJNR Am J Neuroradiol 20: 131-132.
51. Van Laere K, De Ceuninck L, Dom R, et al (2004) Dopamine transporter SPECT using fast kinetic ligands: 123 I-FP-beta-CIT versus 99m Tc-TRODAT-1. Eur J Nucl Med Mol Imaging 31: 1119-1127.
52. Verbeek MM, Willemsen MA, Wevers RA, et al (2008) Two Greek siblings with sepiapterin reductase deficiency. Mol Genet Metab 94: 403-409. doi: 10.1016/j.ymgme.2008.04.003
53. Wüllner U, Reimold M, Abele M, et al (2005) Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol 62: 1280-1285. doi: 10.1001/archneur.62.8.1280
54. Yalcinkaya C, Gibson KM, Gunduz E, et al (2000) MRI Findings in succinic semialdehyde dehydrogenase deficiency. Neuropediatrics 31: 45-46. doi: 10.1055/s-2000-15298
55. Zafeiriou DI, Willemsen MA, Verbeek MM, Vargiami E, Ververi A, Wevers R (2009) Tyrosine hydroxylase deficiency with severe clinical course. Mol Genet Metab 97: 18-20. doi: 10.1016/j.ymgme.2009.02.001
56. Ziyeh S, Berlis A, Korinthenberg R, et al (2002) Selective involvement of the globus pallidus and dentate nucleus in succinic semialdehyde dehydrogenase activity. Pediatr Radiol 32: 598-600. doi: 10.1007/ s00247-002-0717-4
57. Zhou QY, Qualfe CJ, Palmiter RD (1995) Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374: 640-643. doi: 10.1038/374640a0